Friday, February 24, 2017 4:49:17 PM
No, that is not "out of the way"
Read the abstract.
"Nineteen (19) patients diagnosed with GBM were determined to have rapid recurrence following ....... Median overall survival in this cohort from initial GBM diagnosis is 15.1 months..."
I never claimed the 8 were part of the 51, these above 19 were part of the 51. And for them, survival was measured from initial GBM diagnosis.
As it was measured for the remaining patients in the poster. And if you want to compare this group with the ICT107 group, you need to subtract 13 weeks (I was wrong when I said 4 months, in their P2 it was 13 weeks between surgery and randomization).
As noted above, it most definitely is from diagnosis. Surgical diagnosis. That's the only way to confirm GBM (the pathologist makes the diagnosis). And it's is a very easy date to nail down considering that to be in the INFO arm, you needed to have surgery at a trial site and signed the consent for tumor collection.
It was 14.75 months from the time of Baseline (in the ICT107 trial which was 13 weeks after surgery).
From the NWBO press release:
"According to initial analyses, the median Overall Survival for all 55 patients is 18 months"
And that 18 months is from surgery.
subtract 13 weeks and you get 14.75 months from the corresponding randomization time for ICT-107 group you are trying to compare with.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM